-
Mashup Score: 3
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Source: www.onclive.comCategories: General Medicine NewsTweet
Treatment with the oral TKI showed promising responses among 2 subgroups of patients with advanced, HER2-mutant non–small cell lung cancer.
Sevabertinib Induces Durable Response in Advanced HER2-Mutant NSCLC #lungcancer #NSCLC #ASCO25 @herbloong @CUHKofficial @ASCO https://t.co/K8vwka23Ga